Outsourcing

Editor of Pharmaceutical Technology Europe

Articles

More complex and challenging compounds require a more tailored approach to formulation strategies.

Unique Molecules Push Formulation Boundaries 

Bill Connell is a principal and supply chain practice leader at Tunnell Consulting.

Contract service providers offer vital services to bio/pharma companies of all sizes. Establishing an effective working relationship and managing operations are key to avoiding compliance issues.

Build CMO Relationships with Effective Management Practices

Catalent has unveiled plans to invest in a European center of excellence for clinical biologics formulation development and drug product fill/finish services at its facility in Limoges, France.

Catalent Invests Millions to Create European Clinical Manufacturing Center of Excellence

The acquisition will give the CDMO additional clinical filling options in Europe, which is expected to come online in 2021.

Vetter Expands Fill/Finish Capacity with Acquisition of New Site in Austria

Lonza is making additional investments in its global particle engineering network for expanded capacity and specialized capabilities.

Lonza Announces Additional Investments in Global Particle Engineering Services

Demand for custom drug delivery solutions is increasing and bringing forth an exciting period of valuable, innovative development opportunities.

Demand for Custom Dosage Forms Fuels Innovation

Susan Haigney is managing editor of Pharmaceutical Technologyand Pharmaceutical Technology Europe, susan.haigney@ubm.com.

The COVID-19 pandemic has created a rise in demand for R&D and a shift in focus for some contract organizations.

Contractors Balance Increased Demand During COVID-19

FDA approved hydroxychloroquine sulfate for emergency use as a treatment for some hospitalized patients with COVID-19. 

AMRI Announces Increased Production of Hydroxychloroquine Sulfate for COVID-19 Treatment

Rita Peters is editorial director of Pharmaceutical Technology, Pharmaceutical Technology Europe, and BioPharm International.

Will moving at “warp speed” to develop a vaccine impact efficacy or safety?

How Fast Is Too Fast?

Catalent and Johnson & Johnson announce joint investment and tech transfer to prepare for rapid scale-up and segregated cGMP commercial manufacturing capacity.

Contract Development Services